Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.
Open Access
- 1 September 1988
- journal article
- research article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 8 (9), 3969-3973
- https://doi.org/10.1128/mcb.8.9.3969
Abstract
P185, the product of the neu/erbB2 proto-oncogene, is oncogenically activated by a point mutation that substitutes glutamic acid for valine in the transmembrane domain of the protein. We have found that the transforming form of p185 differs from its normal counterpart in inducing increased tyrosine phosphorylation of other proteins in vivo and in having a much shorter half-life. These results support the model that the transforming p185 resembles a ligand-activated receptor.This publication has 48 references indexed in Scilit:
- Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-srcCell, 1987
- Activation and suppression of pp60c-src transforming ability by mutation of its primary sites of tyrosine phosphorylationCell, 1987
- Transforming potential of the c-fms proto-oncogene (CSF-1 receptor)Nature, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptorNature, 1986
- The neu oncogene encodes an epidermal growth factor receptor-related proteinNature, 1986
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985
- Protein phosphorylation at tyrosine is induced by the v-erbB gene product in vivo and in vitroCell, 1985
- Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogeneNature, 1984
- Expression of v-src and chicken c-src in rat cells demonstrates qualitative differences between pp60v-src and pp60c-srcCell, 1984